Inavolisib or Placebo in Combination With Palbociclib and Fulvestrant in Patients With PIK3CA Mutated, Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer: Phase III INAVO120 Primary Analysis

Komal L. Jhaveri, MD, FACP, presents key data on the addition of inavolisib to palbociclib and fulvestrant vs palbociclib and fulvestrant alone in select patients with PIK3CA-mutated, hormone receptor–positive, HER2-negative, locally advanced, or metastatic breast cancer.